Foresight Diagnostics

Will we see you at #ASH25? Foresight will present the first real-world study of ctDNA dynamics in treated #LBCL, showcasing how #ultrasensitive MRD detection can guide personalized treatment. Excited to connect on the next stage of MRD-driven care: bit.ly/47kdmQE

Spirits are high in the office this week with a little Halloween fun! Our team came together for some friendly competition during our costume contest, sharing laughs and creativity, along with some impressive outfits. Thanks to everyone who joined in!

Welcome Carrina Cappadona to the team! As our new VP of Patient and Client Experience, Carinna will lead efforts to ensure that patients, clinicians, and providers are supported as we work to develop innovative diagnostic tests to advance cancer drug development and patient care.

Our Foresight CLARITY™ MRD platform detects the presence of #MRD from circulating tumor DNA (ctDNA) with sensitivity to multiple cancers.

Learn about how Foresight CLARITY™ is shaping the next-gen of cancer monitoring: bit.ly/4mpDDRW

#UltrasensitiveScience

Excited to attend #ESMO2025 in Berlin!

Foresight team members will be onsite connecting with experts on the latest breakthroughs in #oncology. Curious about our #MRD detection technology, #ForesightCLARITY? Let’s connect!

Reach out here: bit.ly/4mZE7yK

#BeyondClarity #UltrasensitiveScience

Episode 65. Circulating Tumor DNA in DLBCL with Dr. Ash Alizadeh and Dr. David Russler-Germain Podcast Episode · Blood Cancer Talks · 09/24/2025 · 53m

Curious how ctDNA could reshape care for aggressive cancers like #DLBCL? Hear from co-founder Ash Alizadeh on Blood Cancer Talks on its transformative potential, from advances in detection to breakthrough clinical data. Listen here: bit.ly/4mBkyfr

Excited to join #FierceBiotechWeek! Our CBO John Truesdell and Allogene Therapeutics CMO Zachary Roberts will discuss how next-gen #MRD is reshaping oncology, driving personalized care, advancing therapies, and informing decisions to improve outcomes. Register here: bit.ly/4nk0C1A

The Foresight team was proud to support Blood Cancer United at our local #LightTheNight Walk! We sponsored the walkway and cheered on patients, survivors, families, and supporters. It was an inspiring night honoring those impacted by blood cancers and funding life-saving research.

We had a great time at World CB & CDx Summit this week! A highlight was hosting a lunch & learn with QIAGEN, where we explored opportunities for MRD-driven companion diagnostic development and distribution.

Connect with our BD team to learn more about us: bit.ly/4mZE7yK

We’re thrilled to welcome McKenzie Carlisle, PhD, to the Foresight team! As our new Senior Director of Regulatory Operations and Compliance, she’ll lead regulatory strategy for our IVD pipeline, helping drive innovative diagnostics to advance oncology drug development and patient care.

On #WorldCancerResearchDay, we reaffirm our goal to give patients actionable data when it matters most. With Foresight CLARITY™, powered by our PhasED-Seq™ technology, we aim to uncover residual disease at key points in treatment. Learn more about us: bit.ly/4pwH3EY

The Foresight team is excited to join Blood Cancer United's #LightTheNight walk in Denver on Sept. 25 to honor and support those impacted by #bloodcancer. Walk with us, or find an event near you to help raise funds for life-saving research. Sign up here: bit.ly/3IjzEYS

Looking forward to the Liquid Biopsy Symposium! Michiel Pegtel, PhD and HOVON will present on the value of Foresight CLARITY™ #MRD at end of #DLBCL therapy in a real-world cohort and founder Max Diehn, MD, PhD, will present on advances in liquid biopsies: bit.ly/4mSKNPL

Excited to be at the upcoming World CB & CDx Summit! Meet us to learn about our technology for detecting #MRD with unmatched sensitivity in cancer types. Ask about our QIAGEN partnership to develop CDx kits for #lymphoma and our global CDx capabilities. More details: world-cdx.com

Reflecting on a successful #WCLC25! Our team shared our work with University Health Network Toronto on advancing ctDNA analysis in #NSCLC with Foresight CLARITY™ and connected with colleagues, collaborators and others dedicated to improving outcomes in #lungcancer. More details: bit.ly/4gmQh2t

On #WLAD we recognize challenges patients face post-treatment: ~30% of #DLBCL patients relapse, often taking 1–2 years to confirm with current methods. Foresight CLARITY™ seeks to detect relapse sooner, enabling precise care. Learn more: bit.ly/45yFqgO #BloodCancerMonth

Next-Gen MRD Testing: Foresight’s Leap in Sensitivity with Jake Chabon and Dave Kurtz Catching a cancer relapse before any scan could see it is the ultimate goal for minimal residual disease or MRD testing.

How is research shaping the future of cancer care? Hear from our CEO & CMO on Mendelspod on Foresight’s origin story, our next-gen #MRD testing with unmatched sensitivity, detecting relapse earlier, and what’s next for cancer care. Listen here: bit.ly/46pUm1A
#Oncology

Company Announcement: Foresight Diagnostics and Roche Enter Licensing Agreement for PhasED-Seq™ Technology in Non-Hodgkin’s Lymphoma. The Agreement Closes the Litigation Between the Parties. More information: bit.ly/46fSoki

#MRD #Oncology

Our team is at #WCLC25 this weekend! We’re sharing data with University Health Network Toronto on ctDNA analysis from the ctDNA-Lung-DETECT study in #NSCLC using Foresight CLARITY™, our ultrasensitive next-gen assay, showing high #MRD detection. Details: bit.ly/4g9ynQN

Don’t miss our webinar on Friday, 9/12 with QIAGEN and Precision Medicine Online! We’ll cover ultra-sensitive #MRD in lymphoma, recent data, and how our collaboration combines Foresight’s ultrasensitive technology with Qiagen’s NGS workflows and diagnostics. Register here: bit.ly/464FJBD

Check out this new publication by lead author Paolo Strati in Nature Communications from a Phase 2 trial in patients with advanced #follicularlymphoma using Foresight CLARITY™, achieving ultra-sensitive #MRD detection and outcome prediction. Read here: bit.ly/3I3Vdg4

Come see us at #WCLC25 in September, where Foresight is presenting in partnership with University Health Network Toronto, featuring ctDNA-MRD analysis utilizing our Foresight CLARITY™ assay in patients with #NSCLC.

Session information: bit.ly/3VjxStI
To meet with us: bit.ly/4mZE7yK

Check out our publication in Journal of Clinical Oncology, showing Foresight CLARITY™ delivered greater prognostic accuracy than PET/CT at end of therapy in #LBCL, reinforcing the role of ultrasensitive #MRD testing for remission assessment. Read more: bit.ly/4lz93oi

Jeff Gregg, VP of Medical Affairs at Foresight, will be at the 17th Annual #NextGenerationDxSummit in D.C.!

He’ll discuss how #MRD is moving beyond early detection to help drive clinical decision making, enabled by ultra-sensitive assays like Foresight CLARITY™.

What a great day! Thanks to all our team members who joined us for food, fun and giving back. Shout out to our team members for taking the plunge in the dunk tank to raise funds for The Leukemia & Lymphoma Society Denver!

#ForesightCLARITY #PrecisionOncology #MRDdetection #Biotechnology #startup

Seeing What PET Misses The inclusion of molecular MRD testing in NCCN guidelines marks a turning point for personalized lymphoma diagnostics

Check out an interview our CMO David Kurtz, MD, PhD, did with The Pathologist about how #MRD testing is advancing personalized lymphoma care, and how real-world data supports Foresight CLARITY™ for use at end of #DLBCL treatment. Full article: bit.ly/3IyWKL4

ASCO® 2025 Insights: Sequencing-Guided Chemo Optimization Using ctDNA in Newly Diagnosed DLBCL - The SHORTEN-ctDNA Trial A video from Hua-Jay Cherng (as part of 2025 ASCO® Annual Meeting Insights Hub), posted on Jun 5, 2025.

This #ASCO2025 Insights video highlights @columbiauniversity.bsky.social’s innovative SHORTEN-ctDNA trial using Foresight CLARITY™ MRD to help personalize #chemotherapy treatment and avoid unnecessary toxicity. Watch here: bit.ly/408uxR9
Read the data: bit.ly/43LAvbs

Dr Abramson on ASCO 2025 DLBCL Updates: What's New? Jeremy S. Abramson, MD, discusses pivotal advancements in DLBCL from the 2025 American Society of Clinical Oncology Annual Meeting.

Dr. Jeremy Abramson (Mass General/Harvard) spotlighted Foresight CLARITY #MRD detection in a prospective, real-world cohort presented at #ASCO2025.

At Foresight, we’re proud to back tools driving smarter interventions and personalized treatment. Watch here: bit.ly/4kb7o7D

This Independence Day, we celebrate freedom, resilience, and the pursuit of better health. We’re committed to advancing #cancer detection through #MRD testing — because independence in health matters. #IndependenceDay #FourthOfJuly #PrecisionMedicine #Oncology #MRD

Our VP of Medical Affairs will participate in a panel titled “Defining Endpoints & MRD Strategies to Advance Precision Oncology Trials” at the Liquid Biopsy for Precision Oncology Summit in Boston! #MRD #ctDNA #CancerDiagnostics #PrecisionMedicine #LiquidBiopsy #ClinicalTrials